2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LOCATELLI, F. Articles by SPOTTI, D. Search for Related Content PubMed PubMed Citation Articles by LOCATELLI, F. Articles by SPOTTI, D.

Survival and Development of Cardiovascular Disease by Modality of Treatment in Patients with End-Stage Renal Disease

Lambardy Dialysis and Transplant Registry, Milan, Italy.¹.

Correspondence to Dr. Francesco Locatelli, Department of Nephrology and Dialysis, A. Manzoni Hospital, Via Dell'Eremo 9/11, 23900 Lecco, Italy. Phone: 39-0341-489850; Fax: 39-0341-489860; E-mail: nefrologia{at}ospedale.lecco.it

Abstract. Patients undergoing dialysis are at high risk for cardiovascular disease (CVD). The aim of this study was to evaluate the influence of hemodialysis (HD) versus peritoneal dialysis (PD) on survival and the risk of developing de novo CVD. Of the 4191 patients with end-stage renal disease (ESRD) who started renal replacement treatment (RRT) in Lombardy between 1994 and 1997, 4064 (who were on dialysis 30 d after the start of RRT) were considered for survival analysis: 2772 were on HD (mean age 60.9 yr; 21.2% diabetic) and 1292 on PD (mean age 63.6 yr; 16% diabetic). The 3120 patients who were free of CVD at the start of RRT were included in the analysis of the risk of developing de novo CVD. HD and PD were compared by use of a Cox-regression proportional hazard model, stratified by diabetic status; the explanatory covariates were age and gender. The death rate was 13.3 per 100 patient-years (13.0 on HD and 13.9 on PD); 197 (6.3%) of the 3120 patients included in the CVD analysis developed de novo CVD (128 on HD and 69 on PD). After adjustment for age, gender, and established CVD and stratification by diabetic status, there was no significant between-treatment difference in 4-yr survival (relative risk [RR], 0.91; 95% confidence interval [CI], 0.79 to 1.06). The risk of de novo CVD did not differ significantly by treatment modality (RR, 1.06; 95% CI, 0.79 to 1.43). The risk of mortality and de novo CVD for new patients with ESRD assigned to HD or PD was similar in Lombardy in the period 1994 through 1997.

This article has been cited by other articles:

				K. Denhaerynck, D. Manhaeve, F. Dobbels, D. Garzoni, C. Nolte, and S. De Geest PREVALENCE AND CONSEQUENCES OF NONADHERENCE TO HEMODIALYSIS REGIMENS Am. J. Crit. Care., May 1, 2007; 16(3): 222 - 235. [Abstract] [Full Text] [PDF]

				W. Van Biesen, F. Verbeke, and R. Vanholder Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro peritoneal dialysis Nephrol. Dial. Transplant., January 1, 2007; 22(1): 53 - 58. [Full Text] [PDF]

				L. Segall and A. Covic Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro haemodialysis Nephrol. Dial. Transplant., January 1, 2007; 22(1): 59 - 63. [Full Text] [PDF]

				J. K. Inrig, J. L. Sun, Q. Yang, L. P. Briley, and L. A. Szczech Mortality by Dialysis Modality among Patients Who Have End-Stage Renal Disease and Are Awaiting Renal Transplantation Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 774 - 779. [Abstract] [Full Text] [PDF]

				B. G. Jaar, J. Coresh, L. C. Plantinga, N. E. Fink, M. J. Klag, A. S. Levey, N. W. Levin, J. H. Sadler, A. Kliger, and N. R. Powe Comparing the Risk for Death with Peritoneal Dialysis and Hemodialysis in a National Cohort of Patients with Chronic Kidney Disease Ann Intern Med, August 2, 2005; 143(3): 174 - 183. [Abstract] [Full Text] [PDF]

				G. Schulman Mortality and Treatment Modality of End-Stage Renal Disease Ann Intern Med, August 2, 2005; 143(3): 229 - 231. [Full Text] [PDF]

				Z. T. Bloomgarden The European Association for the Study of Diabetes Diabetes Care, May 1, 2005; 28(5): 1250 - 1257. [Full Text] [PDF]

				M. V. Rocco, A. K. Cheung, T. Greene, G. Eknoyan, and for the Hemodialysis Study Group The HEMO Study: applicability and generalizability Nephrol. Dial. Transplant., February 1, 2005; 20(2): 278 - 284. [Full Text] [PDF]

				G. Mircescu, D. Capsa, M. Covic, M. G. Caprioara, G. Gluhovschi, O. Golea, N. Ursea, L. Garneata, V. Cepoi, N. Constantinovici, et al. Nephrology and renal replacement therapy in Romania--transition still continues (Cinderella story revisited) Nephrol. Dial. Transplant., December 1, 2004; 19(12): 2971 - 2980. [Abstract] [Full Text] [PDF]

				A. W. Wu, N. E. Fink, J. V.R. Marsh-Manzi, K. B. Meyer, F. O. Finkelstein, M. M. Chapman, and N. R. Powe Changes in Quality of Life during Hemodialysis and Peritoneal Dialysis Treatment: Generic and Disease Specific Measures J. Am. Soc. Nephrol., March 1, 2004; 15(3): 743 - 753. [Abstract] [Full Text] [PDF]

				F. Locatelli, P. Pozzoni, and L. Del Vecchio Renal Replacement Therapy in Patients with Diabetes and End-Stage Renal Disease J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S25 - 29. [Abstract] [Full Text]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673